 OncLive | Pfizer Discontinues Late-Stage Trial of Inotuzumab Ozogamicin - OncLive OncLive The phase III study explored inotuzumab ozogamicin plus rituximab specifically as a treatment for patients with relapsed or refractory CD22-positive, aggressive non-Hodgkin lymphoma (NHL) who were not candidates for high-dose chemotherapy, this ... Pfizer Halts Phase III Trial of Cancer Drug in NHL Due to Futility Non-Hodgkin Rx Trial Halted Pfizer drug fails in Phase III NHL trial |
